Low-dose fluoride in postmenopausal women: A randomized controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 6, 2013, Pages 2301-2307

  Grey, Andrew ^a   Garg, Sanjay ^a,b   Dray, Michael ^a,c   Purvis, Lauren ^a   Horne, Anne ^a   Callon, Karen ^a   Gamble, Greg ^a   Bolland, Mark ^a   Reid, Ian R ^a   Cundy, Tim ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c WAIKATO HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; FLUORIDE; PLACEBO; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG;

AGED; ANKLE FRACTURE; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE TURNOVER; CALCANEUS FRACTURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOOT FRACTURE; FOREARM; GASTROINTESTINAL SYMPTOM; HIP; HUMAN; HUMAN TISSUE; HUMERUS FRACTURE; LEG PAIN; LOW DRUG DOSE; LUMBAR SPINE; MAJOR CLINICAL STUDY; METATARSUS FRACTURE; MORPHOMETRICS; OSTEOPENIA; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIB FRACTURE; UNIVERSITY HOSPITAL;

AGED; BONE DENSITY; BONE REMODELING; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUORIDES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE;

EID: 84878518653     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-4062     Document Type: Article

References (17)

1. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276-1287.
2. Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol. 2012;8:81-91.
3. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441. (Pubitemid 32402100)
4. Farley JR, Wergedal JE, Baylink DJ. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science. 1983;222:330-332. (Pubitemid 13013396)
5. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990;322:802-809. (Pubitemid 20094143)
6. Kleerekoper M, Peterson EL, Nelson DA, et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int. 1991;1:155-161.
7. Lundy MW, Stauffer M, Wergedal JE, et al. Histomorphometric analysis of iliac crest bone biopsies in placebo-treated versus fluoride-treated subjects. Osteoporos Int. 1995;5:115-129.
8. Pak CY, Sakhaee K, Piziak V, et al. Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial. Ann Intern Med. 1994;120:625-632. (Pubitemid 24106173)
9. Reginster JY, Meurmans L, Zegels B, et al. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med. 1998;129:1-8. (Pubitemid 28304646)
10. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int. 1998;8:4-12. (Pubitemid 28085478)
11. Reid IR, Cundy T, Grey AB, et al. Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2007;92:2446-2452. (Pubitemid 47037341)
12. Vestergaard P, Jorgensen NR, Schwarz P, Mosekilde L. Effects of treatment with fluoride on bone mineral density and fracture risk - a meta-analysis. Osteoporos Int. 2008;19:257-268.
13. Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97:286-292.
14. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595-610.
15. Alexandersen P, Riis BJ, Christiansen C. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocrinol Metab. 1999;84:3013-3020. (Pubitemid 30646915)
16. Padhi D, Stouch B, Jang G, et al. Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res. 2007;22:S37.
17. Glover SJ, Gall M, Schoenborn-Kellenberger O, et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res. 2009;24:389-397.